SCHEMBL7241306

SCHEMBL7241306

Cc1cncn1C/C(=C\c1ccc(C(=O)O)c(-c2ccccc2)c1)c1ccc(F)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
POLB P06746 1/20 0.35
LDHA P00338 1/20 0.34
GSK3B P49841 2/20 0.34
QPCT Q16769 2/20 0.34
BCL2L1 Q07817 1/20 0.34
BAD Q92934 1/20 0.34
S1PR1 P21453 1/20 0.34
PPARG P37231 3/20 0.33
MYC P01106 2/20 0.33
LTB4R2 Q9NPC1 1/20 0.33
PTGS1 P23219 1/20 0.32
PTGS2 P35354 1/20 0.32
CYP19A1 P11511 2/20 0.32
FNTA P49354 1/20 0.32
FNTB P49356 1/20 0.32
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7241309 1.00 MEN1 (0.35) MEN1KMT2ACYP11B1CYP11B2POLB
SCHEMBL7239569 0.91 SLC6A4 (0.40) KMT2ACYP11B1CYP11B2QPCTFNTA
SCHEMBL7239567 0.91 SLC6A4 (0.40) KMT2ACYP11B1CYP11B2QPCTFNTA
SCHEMBL7703319 0.84 FNTA (0.41) FNTAFNTB
SCHEMBL7703436 0.84 FNTA (0.53) FNTAFNTB
SCHEMBL7703311 0.84 FNTA (0.41) FNTAFNTB
SCHEMBL7703440 0.84 FNTA (0.53) FNTAFNTB
SCHEMBL7708946 0.82 TTR (0.39) MEN1KMT2APOLBMYCPTGS1
SCHEMBL7708941 0.82 TTR (0.39) MEN1KMT2APOLBMYCPTGS1
SCHEMBL8228722 0.77 CYP19A1 (0.45) POLBCYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030220495-A1 Inhibitors of farnesyl protein transferase ZENECA LIMITED AND ZENECA PHARMA S.A. 2003-11-27 US disclosed
US-6414145-B1 TREATING CANCER AND NEUROFIBROMATOSIS ZENECA LIMITED (GB) 2002-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220495-A1 Inhibitors of farnesyl protein transferase KRAS, FNTA, FNTB MEN1 2044/4885KMT2A 2632/4885CYP11B1 639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.